24/7 Market News Snapshot 18 December, 2024 – Cognition Therapeutics, Inc. Common Stock (NASDAQ:CGTX)

December 18, 2024

DENVER, Colo., 18 December, 2024 (247marketnews.com) – (NASDAQ:CGTX) are discussed in this article.
Cognition Therapeutics, Inc. (NASDAQ:CGTX) is currently generating significant buzz in the market, reflecting a robust pre-market surge of 61.57%, with shares trading at $0.735, up from a previous close of $0.455. This momentum comes alongside an impressive trading volume of 14.41 million shares, indicating heightened investor interest. Analysts are closely monitoring this upward trend, considering it a pivotal moment that may lead to sustained growth for the company.

In addition to its market performance, Cognition Therapeutics recently announced promising topline results from its exploratory Phase 2 study, SHIMMER, which focused on the efficacy of its investigational drug, CT1812, in patients diagnosed with dementia with Lewy bodies (DLB). This pivotal study showcased significant therapeutic responses, achieving substantial improvements across various measures, including behavioral, cognitive, functional, and movement-related aspects. The trial successfully enrolled 130 participants with mild-to-moderate DLB, revealing an impressive 82% reduction in total neuropsychiatric inventory scores, which indicates a notable decrease in anxiety, hallucinations, and delusions compared to the placebo group.

Furthermore, the study highlighted a marked reduction in caregiver distress, suggesting that CT1812 has the potential to not only improve the quality of life for patients but also positively influence the experiences of caregivers. Dr. James E. Galvin, a principal investigator in the trial, expressed optimism about the results, emphasizing the drug’s multifaceted approach to treating DLB.

Cognition Therapeutics’ Chief Medical Officer, Dr. Anthony Caggiano, reiterated the promising implications of CT1812’s neuroprotective efficacy across neurodegenerative disorders and confirmed the trial’s achievement of its primary endpoint of safety and tolerability. The detailed findings will be presented at the upcoming International Lewy Body Dementia Conference, laying the groundwork for late-stage clinical trials as the company continues to advance its commitment to developing innovative therapies for age-related neurodegenerative diseases.

Related news for (CGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.